cancer stem cell Archives - MES https://mes.ulf-kahlert.com/tag/cancer-stem-cell/ Fri, 29 Jul 2022 19:28:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.4 https://mes.ulf-kahlert.com/wp-content/uploads/2021/12/cropped-MES_mit_Schrift_skalpell-32x32.jpg cancer stem cell Archives - MES https://mes.ulf-kahlert.com/tag/cancer-stem-cell/ 32 32 Drug development: Establishment of new gene-therapeutics candidate belonging to the class of polycatisonic phosphorus dendrimer https://mes.ulf-kahlert.com/2022/07/29/drug-development-establishment-of-new-gene-therapeutics-candidate-belonging-to-the-class-of-polycatisonic-phosphorus-dendrimer/ Fri, 29 Jul 2022 19:27:44 +0000 https://mes.ulf-kahlert.com/?p=8349 Herein, we performed the validation of the polycationic phosphorus dendrimer-based approach for small interfering RNAs delivery in cancer stem cell in vitro. As a molecular target, we chose Lyn, a member of the Src family kinases as an example of a prominent enzyme class widely discussed as a potent anti-cancer intervention point. We then showed […]

The post Drug development: Establishment of new gene-therapeutics candidate belonging to the class of polycatisonic phosphorus dendrimer appeared first on MES.

]]> Herein, we performed the validation of the polycationic phosphorus dendrimer-based approach for small interfering RNAs delivery in cancer stem cell in vitro. As a molecular target, we chose Lyn, a member of the Src family kinases as an example of a prominent enzyme class widely discussed as a potent anti-cancer intervention point. We then showed that anti-Lyn siRNA, delivered into Lyn-expressing tumor cell model reduces the cell viability, a fact that was not observed in a cell model that lacks Lyn-expression. Furthermore, we have found that the dendrimer itself influences various parameters of the cells such as the expression of surface markers PD-L1, TIM-3 and CD47, targets facilitating immune cell recognition.

The post Drug development: Establishment of new gene-therapeutics candidate belonging to the class of polycatisonic phosphorus dendrimer appeared first on MES.

]]> Drug development: Synthesis of a new stem cell-directed, anti-metabolic drug https://mes.ulf-kahlert.com/2022/07/29/development-development-synthesis-of-a-new-stem-cell-directed-anti-metabolic-drug/ Fri, 29 Jul 2022 19:20:56 +0000 https://mes.ulf-kahlert.com/?p=8347 The failure of a long-lasting curative therapeutic benefit of currently applied chemotherapies against malignant cancers is suggested to be caused by the ineffectiveness of such interventions on cancer stem cells (CSCs). CD133/AC133 is a cell surface protein previously shown to have potential to identify CSCs in various tumors, including brain tumors. Moreover, an increase in […]

The post Drug development: Synthesis of a new stem cell-directed, anti-metabolic drug appeared first on MES.

]]> The failure of a long-lasting curative therapeutic benefit of currently applied chemotherapies against malignant cancers is suggested to be caused by the ineffectiveness of such interventions on cancer stem cells (CSCs). CD133/AC133 is a cell surface protein previously shown to have potential to identify CSCs in various tumors, including brain tumors. Moreover, an increase in the rate of cellular metabolism of glutamine and glucose are contributors to the fast cellular proliferation of some high-grade malignancies. Inhibition of glutaminolysis by utilizing pharmacological inhibitors of the enzyme glutaminase 1 (GLS1) can be an effective anti-CSC strategy. In this study, the clinical-stage GLS1 inhibitor Telaglenastat (CB-839) was loaded into PEGylated gold nanoparticles equipped with the covalently conjugated CD133 aptamer (Au-PEG-CD133-CB-839) and exposed to a collection of CD133-positive tumor models in vitro.

The post Drug development: Synthesis of a new stem cell-directed, anti-metabolic drug appeared first on MES.

]]>